ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
5
views
0
references
Top references
cited by
4
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
649
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results
Author(s):
M.H. O’Hara
,
E.M. O’Reilly
,
R.A. Wolff
,
MH O'Hara
,
EM O'Reilly
,
RA Wolff
,
M.H. O'Hara
,
E.M. O'Reilly
,
Z.A. Wainberg
,
A.H. Ko
,
O.E. Rahma
,
G.A. FISHER
,
J.P. Lyman
,
C.R. Cabanski
,
J.J. Karakunnel
,
P.F. Gherardini
,
L.J. Kitch
,
S. Bucktrout
,
E Christopher
,
R Mick
,
R Chen
,
O.C Trifan
,
L Salvador
,
J O'Donnell-Tormey
,
R.H. Vonderheide
Publication date:
2021
Journal:
J Clin Oncol
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Bacterial extracellular vesicles
Data availability:
ScienceOpen disciplines:
Molecular medicine
Comments
Comment on this article
Sign in to comment
Similar content
649
The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
Authors:
T Mercade
,
A. Wang-Gillam
,
L. Chen
…
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
Authors:
G Lakatos
,
K. Lee
,
J Siveke
…
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Authors:
K. Lee
,
G Bodoky
,
J. Blanc
…
See all similar
Cited by
4
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Authors:
Nicholas A Ullman
,
Paul R Burchard
,
Richard F. Dunne
…
Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming
Authors:
Ashley Velez-Delgado
,
Katelyn L. Donahue
,
Kristee Brown
…
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Authors:
M.S. Rémond
,
A. Pellat
,
C. Brezault
…
See all cited by